Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
about
Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression.Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation.BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantationThe emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.The role of TLR8 signaling in acute myeloid leukemia differentiation.Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patientsUpdate on toll-like receptor-directed therapies for human diseasePhase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaTLR9 ligation in pancreatic stellate cells promotes tumorigenesisToll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans.Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignanciesObstacles to effective Toll-like receptor agonist therapy for hematologic malignancies.Toll-like receptors: lessons to learn from normal and malignant human B cellsSignificance of toll-like receptors expression in tumor growth and spreading: a short reviewThe role of toll-like receptors in chronic B-cell malignancies.TLR7-expressing cells comprise an interfollicular epidermal stem cell population in murine epidermis.Cancer immunotherapy and nanomedicine.Toll-like Receptors in Chronic Lymphocytic Leukemia.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Toll-like receptor agonists: a patent review (2011 - 2013).Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Modeling the chronic lymphocytic leukemia microenvironment in vitro.The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells.Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival.
P2860
Q31038111-929BA397-7FDE-4596-8A6F-2277E39E9A66Q33494116-26C9AE1E-02C2-4E60-BCDD-AC1907667528Q34041311-8B363995-DE8D-4BDD-9670-E5BC066407BAQ34154994-BB6524BF-214A-4F2F-BE0F-4E85E9F73AD3Q34618829-DB16B814-8848-4E62-BDCE-68AB613AC120Q35058213-F03435BA-43C4-49AB-997F-67A4904E7F8AQ35096709-36808793-FCEC-4FA9-A197-E7F72CF9CD69Q35288072-66F270C7-04A4-4AFF-99ED-068307B245EEQ35528659-04A92FFA-F67C-480C-B1C1-AA75F8C57225Q36171745-09B21124-E329-456A-9168-CD4627B284E5Q36222910-EACCBFEB-27BA-4114-9865-EBB239792C03Q36286020-0D320F7E-2C2B-4CCF-97E8-DCD026A59E9FQ36357873-6DFDF8E0-634C-483F-A29A-8933E1609584Q36465271-2E4923C1-34FF-4043-B15B-43F533125A6AQ36802795-5EFAC6A3-90D6-49FE-9DFA-D0C89222CBEFQ37051022-C447F800-801A-4236-A9BC-0AA32CBB7A08Q37203723-92D6A107-A748-4F99-95BA-D36D2F2A15B1Q37421540-A0DC214B-7ABD-4753-97D3-65D2B57C68DFQ37578343-66974B69-A99D-4F25-A6BA-A5CAACC27BFDQ37733130-699CD914-66C9-425D-B293-80E2F868BD98Q37785836-082CDAFD-4BCF-4A1E-BE93-113E60F316B2Q38042942-C343553C-CD77-4B5D-90E4-12E0C2D9919FQ38059499-DF25BE92-05C6-48A5-AF26-4AE8E8F2EC5AQ38181176-BED8AED5-6060-4C91-AAEA-A5C759525781Q38298483-5189D84B-E80F-4162-AB51-9396B853858CQ38646974-ECC5E3C3-F671-4A37-A86E-FBAE66F9E88DQ38984569-FD71181F-2B06-4911-AE4B-7A8212EB90C8Q39042435-197C3C99-33A5-45E3-9F1B-E9022A1F295BQ39748993-23833639-7F77-45F4-A991-9EAD8848BE8CQ40296275-31DCB2AC-54D3-496E-B044-43ED7E5E1D6EQ52837538-457731B6-859F-47EF-AE31-ECE544AFACE2
P2860
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
@ast
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
@en
type
label
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
@ast
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
@en
prefLabel
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
@ast
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
@en
P2860
P921
P356
P1433
P1476
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
@en
P2093
P2860
P2888
P356
10.1038/SJ.LEU.2404456
P577
2006-10-26T00:00:00Z